1. Home
  2. LINC vs ANNX Comparison

LINC vs ANNX Comparison

Compare LINC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lincoln Educational Services Corporation

LINC

Lincoln Educational Services Corporation

HOLD

Current Price

$36.27

Market Cap

732.0M

Sector

Real Estate

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.48

Market Cap

730.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LINC
ANNX
Founded
1946
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
732.0M
730.4M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
LINC
ANNX
Price
$36.27
$5.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$37.50
$16.50
AVG Volume (30 Days)
472.4K
1.7M
Earning Date
05-26-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.94
EPS
0.23
N/A
Revenue
$261,853,000.00
N/A
Revenue This Year
$9.55
N/A
Revenue Next Year
$8.13
N/A
P/E Ratio
$150.39
N/A
Revenue Growth
32.98
N/A
52 Week Low
$14.10
$1.29
52 Week High
$36.42
$7.18

Technical Indicators

Market Signals
Indicator
LINC
ANNX
Relative Strength Index (RSI) 77.68 52.94
Support Level $21.46 $4.65
Resistance Level N/A $7.18
Average True Range (ATR) 1.86 0.32
MACD 0.72 0.00
Stochastic Oscillator 98.17 78.71

Price Performance

Historical Comparison
LINC
ANNX

About LINC Lincoln Educational Services Corporation

Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: